• 대한두경부종양학회지
• /
• 제3권1호
• /
• pp.25-35
• /
• 1987

Irradiated 88 patients of Maxillary Sinus Carcinoma at Yonsei Cancer Center for 10years between 1971 and 1980 were retrospectively analysed. The majority of patients had very advanced disease(87.5% of $T_3\;and\;T_4$) and 17% of cervical lymph node involvement. 80.6% of all patients were epidermoid type. In 44 cases(50%), irradiation alone was performed. 28 cases(32%) of postoperative radiation after incomplete surgery and the remaining 16 cases(18%) of postoperative radiation after radical surgery were done. The majority of patients except 6 cases had irradiation a dose between 60Gy and 80Gy in 30-40 fractions over 6-8 weeks. The actuarial overall 3 and 5 year survival rate were 362% and 26%, respectively. The actuarial 5 year survival rate for 44 cases of radiation alone group was 14.1%, The actuarial 5 year survival rate for 28 cases of incomplete surgery and postoperative radiation group and 16 cases of radical surgery and postoperative radiation group were 312% and 67.4% respectively. In the actuarial 5 year survival rate according to the stage, stage II, III and IV were 79.5%, 20.9% and 0%. In recent, for the improvement of survival rate of advanced Maxillary Sinus Carcinoma at Yonsei Cancer Center, combined multidisplinary or trimodal treatment modality have been applied and in near time the more excellent results expect to be analyse.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제13권1호
• /
• pp.110-116
• /
• 1991

하악골 골절시 감염으로 인한 합병증에는 비유합, 부정유합, 감염에 의한 골수염, 치아 및 지지골 상실, 국소부위로부터 인접부위로 감염확장 등이 있다. 그 원인으로는 크게 국소요인과 전신요인으로 분류되는데 국소요인으로는 부적절한 고정과 수복, 감염 및 개조된 혈액공급을 들 수 있고 전신 요인으로는 부적절한 고정과 수복, 감염 및 개조된 혈액 공급을 들 수 있는 전신요인으로는 환자의 나이 및 대상장애 질환이나 primary bone disease, 영양결핍을 들 수 있다. 악골골절과 관련된 골수염은 조기에 적절한 고정 및 치료, 항생제 요법, 골절선상의 치아에 대한 치료, 전신적 저항성을 항진 시킴으로서 예방할 수 있다. 본 저자들은 하악골 골절수 이차감염으로 인한 골수염에서 골 이식의 일반적인 원칙인 감염이 없는 부위가 아닌 염증이 존재한 부위에 유리장골 이식술과 고압산소 요법을 병행하여 양호한 결과를 얻었기에 이에 보고하는 바이다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권15호
• /
• pp.6267-6272
• /
• 2015

Background: Extra nodal lymphoma (ENL) constitutes about 33 % of all non-Hodgkin's lymphoma. 18-28% develops in the head and neck region. A multimodality treatment with multi-agent chemotherapy (CT) and radiotherapy (RT) is considered optimum. Materials and Methods: We retrieved the treatment charts of patients of HNENL treated in our institute from 2001-2012. The charts were reviewed and the demographic, treatment details and outcome of HNENL patients were retrieved using predesigned pro-forma. Results: We retrieved data of 75consecutive patients HNENL. Median age was 47years (Range: 8-76 years). Of the 75 patients 51 were male and 24 were female. 55patients were evaluable. The patient and tumor characteristics are summarized in Table 1. All patients were staged comprehensively with contrast enhanced computed tomography of head, neck, thorax, abdomen, pelvis and bone marrow aspiration and biopsy 66 patients received a combination multi-agent CT with CHOP being the commonest regimen. 42 patients received 4 or lesser number of cycles of chemotherapy whereas 24received more than 4 cycles chemotherapy. Post radiotherapy, 41 out of 42 patients had a complete response at 3 months. Only 21patients had a complete response after chemotherapy. All patients received radiation (mostly involved field radiation) as a part of the treatment. The median radiation dose was 45 Gray (Range: 36 Gray-50 Gray). The radiation was planned by 2D fluoro simulation based technique in 37cases and by 3 Dimensional conformal radiation therapy (3DCRT) in 36 cases. Two patients were planned by the intensity modulated radiation therapy (IMRT) technique. IMRT was planned for one thyroid and one nasal cavity primary. 5 patients experienced relapse after a median follow up of 19 months. The median survival was not reached. The estimated two and three year survival were 92.9% (95%CI- 68.6- 95.35) and 88% (95%CI- 60.82 - 92.66) respectively. Univariate analysis revealed higher stage and poorer baseline performance status to be significantly associated with worse progression free survival. 5 patients progressed (relapse or primary disease progression) after treatment. Of the 5 patients, two patients were primary orbital NHL, two patients had NHL nasal cavity and one was NHL thyroid. Conclusions: Combined modality treatment in HNENL confers excellent disease control with acceptable side effects.

• 대한관절경학회지
• /
• 제9권2호
• /
• pp.137-142
• /
• 2005

목적: 급성 전방 십자 인대 파열 환자에서 관절경을 이용한 최소한의 절개에 의한 봉합술 후 조기 운동을 시행하여 그 결과를 알아보는데 있다. 대상 및 방법: 2001년 1월부터 2002년 12월까지 슬관절의 급성 전방 십자 인대 파열로 내원하여 인대 봉합술로 치료받은 환자 중 최소 6개월 이상 추시 관찰되었던 38명(39례)를 대상으로 하였으며, 환자의 평가는 이학적 검사, KT-10000을 이용한 전방 전위 검사 및 Lysholm평가를 이용하여 수술결과를 파열양상, 활막의 상태, 내측 측부 인대 손상 여부등에 따라 분석하였다. 결과: 수술후 운동장해는 근위부 및 원위부의 복합파열과 내측 측부 인대 동반손상시 빈도가 의미있게 높았으며 근위부 단독파열과 활막의 파열이 없는 경우 의미있게 낮은 결과를 보였다. 전방 불안정성은 근위부 파열만 있는 경우 의미있게 적었으며 복합파열과 활막의 손상이 심할수록 전방 전위가 의미있게 증가하는 결과를 보였다. 결론: 급성 전방 십자 인대 손상의 치료로 관절경적 봉합술은 근위부 단독파열이면서 활막손상이 없는 경우에 있어서 결과가 좋은것을 알 수 있었다.

• Journal of Oral Medicine and Pain
• /
• 제30권1호
• /
• pp.25-34
• /
• 2005

측두하악장애 및 구강안면통증 환자들 중 근막통증에 의한 기능제한이나 통증을 호소하는 경우를 흔히 볼 수 있다. 근막통증환자를 치료할 때 여러 가지 물리치료가 유용하지만, 즉각적인 통증완화효과를 나타내는 발통점주사요법이 근막통증의 치료로서 널리 적용되고 있다. 발통점주사요법에 흔히 사용하는 화학약제로 생리식염수, 국소마취제, 스테로이드 등이 있으며, 국소마취제는 근육에 대한 부작용이 보고되어 있어 사용상 주의가 필요하다. 이 연구는 상품화된 lidocaine과, dexamethasone 주사제의 혼합용액을 근육내 주사한 후 조직학적 변화를 관찰함으로써 근육에 대한 위해성 여부를 평가하고자 하였다. 또한 용액의 농도에 따라 각각 조직학적 변화를 관찰함으로써 위해성이 없는 적정한 농도를 제시하고자 하였다. 이 연구에서는 생후 9주된 BALB/c 생쥐 (자성) 63마리를 7군으로 분류하여, 앞정강근 (전경골근, tibialis cranialis) 에 각각 생리식염수, dexamethasone, 2.0% lidocaine, 생리식염수와 혼합한 1.0% lidocaine, 생리식염수와 혼합한 1.5% lidocaine, dexamethasone과 혼합한 1.0% lidocaine, dexamethasone과 혼합한 1.5% lidocaine을 주사하였다. 그 후 1일, 7일, 14일째에 희생시켜 실험부위를 절취한 후 조직절편을 만들어 HE염색과 Van-Gieson염색을 거쳐 광학현미경으로 관찰하여 다음의 결론을 얻었다. Lidocaine과 dexamethasone의 혼합용액을 근육내 주사하였을 때, lidocaine의 농도가 1.5% 이하인 경우 조직학적으로 유해하지 않았으며, 통증완화효과와 항염증작용을 동시에 기대할 수 있을 것으로 생각된다. 향후 상기 혼합용액을 발통점주사요법의 약제로 사용할 경우, 인체에서도 동일한 결과가 나올 것인가에 대해서는 추가적인 연구가 필요하다.

• Radiation Oncology Journal
• /
• 제5권2호
• /
• pp.83-95
• /
• 1987

온열요법은 조직에 $40^{\circ}C-44^{\circ}C$의 열을 가함으로서 방사선에 저항성이 큰 DNA합성기의 세포 및 pH가 낮은 세포에 민감하게 작용하는 생물학적 효과를 암 치료에 이용하는 것이다. 그러나 온열요법은 방사선과의 병행요법에 의하여 발생되는 열증강율 및 치료 이득이 방사선량, 열량, 온도, 가열시간, 온도분포, 조사시간 등에 민감하고 변화가 많으므로 객관적인 치료효과와 통일된 치료방법을 결정하기가 어렵다. 저자는 2450MHz, 100watt의 마이크로파 온열기구와 조직등가인 팬톱을 직접제작하여 예비측정을 통해 방열 조사조건과 방법을 결정한 후 생물학적 반응을 관찰하기 위하여 102마리 흰쥐 소장 및 대장의 조직학적 면화를 관찰하고 열증강율에 따른 효과를 비교 평가하여 다음과 같은 결론을 얻었다. 1 온열요법 단독으로는 소장과 대장의 조직학적 면화는 볼 수 없었다. 2. 방사선 조사 단독군과 병행군에서 소장 및 대장의 점막상피 괴사는 방사선 조사 6Gy에서 관찰되었으며 방사선량의 증가와 관찰시간 경과에 따라 그 정도가 심하여졌다. 3. 방사선 조사 단독군과 병행군에서 소장 및 대장의 근육층의 괴사는 방사선 조사 10Gy에서 관찰되기 시작하였으며 관찰시간의 경과에 따라 그 정도가 심하여졌다. 4. 방사선 조사와 온열요법 병행군에서 소장과 대장의 조직학적 변화(점막상피와 근육층의 괴사)를 관찰하여 열증강율은 증가되지 않았다.

• Radiation Oncology Journal
• /
• 제29권4호
• /
• pp.260-268
• /
• 2011

Purpose: To evaluate the treatment outcome and prognostic factor after postoperative radiotherapy in retroperitoneal sarcoma. Materials and Methods: Forty patients were treated with surgical resection and postoperative radiotherapy for retroperitoneal sarcoma from August 1990 to August 2008. Treatment volume was judged by the location of initial tumor and surgical field, and 45-50 Gy of radiation was basically delivered and additional dose was considered to the high-risk area. Results: The median follow-up period was 41.4 months (range, 3.9 to 140.6 months). The 5-year overall survival (OS) was 51.8% and disease free survival was 31.5%. The 5-year locoregional recurrence free survival was 61.9% and distant metastasis free survival was 50.6%. In univariate analysis, histologic type (p = 0.006) was the strongest prognostic factor for the OS and histologic grade (p = 0.044) or resection margin (p = 0.032) had also effect on the OS. Histologic type (p = 0.004) was unique significant prognostic factor for the actuarial local control. Conclusion: Retroperitoneal sarcoma still remains as a poor prognostic disease despite the combined modality treatment including surgery and postoperative radiotherapy. Selective dose-escalation of radiotherapy or combination of effective chemotherapeutic agent must be considered to improve the treatment result especially for the histopathologic type showing poor prognosls.

• 대한후두음성언어의학회지
• /
• 제19권2호
• /
• pp.128-132
• /
• 2008

Background: Laryngeal contact granuloma is an inflammatory hypertrophic granulation tissue arising at around the vocal process of arytenoid cartilage. Various approaches are currently used for the treatment, but a solid guideline has not been established. Objectives: We aimed to compare the each treatment modality in the hope of suggesting a guideline for the successful management of laryngeal contact granuloma. Method: Eighty-seven treatment cases of 56 patients were analyzed. Cases having recent intubation history were excluded from the study. All patients received vocal hygiene education. Proton pump inhibitors (PPI, N = 33) or H2 receptor antagonists ($H_{2}RA$, N =26) were used as a first-line treatment. Among the non-responders to $H_{2}RA$, 11 cases received PPI as a second-line therapy. Eight cases received botulinum toxin injection and 9 cases had laryngomicrosurgical removal. Results: As an initial therapy, response rate to PPI and $H_{2}RA$ was 60.6% and 38.5% respectively, which was not statistically different (p=0.091). Response rate of PPI as the second-line therapy was 36.3% (p=0.162 when compared to that of first-line PPI therapy). Response rate of Botulinum toxin injection was 75%. All cases of surgical removal recurred in a relatively short period (mean 1.9months). Conclusion: In patients having laryngeal contact granuloma, combined therapy with vocal hygiene education and PPI medication would provide more than 60% of therapeutic response. Botulinum toxin injection is highly effective even in non-responders to antireflux therapy. The only indications of surgery are to resolve diagnostic doubt or to treat acute airway compromise.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권1호
• /
• pp.327-330
• /
• 2014

Background: Ewing sarcoma is a small round cell tumor arising from soft tissue and bone that predominantly affects children and adolescents. The most unfavorable prognostic factor is the presence of distant metastasis at the time of diagnosis. Materials and Methods: The records of 26 Ewing sarcoma patients (14 male, 12 female) were re-evaluated retrospectively. Results: The median age was 26.5 (19-42) years. Eight patients (31%) showed a primary tumor in their extremities, 8 (31%) in the thorax, 4 (15%) at the vertebra, 4 (15%) in the head and neck, and 2 (8%) in the abdomen. Five patients (19%) had distant metastasis at diagnosis. The median progression-free survival was 72 months and 10 months in localized and metastatic disease, respectively (p=0.005). The overall survival rate was 19 months in metastatic disease, and the 5-year overall survival rate was 64% in localized disease (p=0.006). Patients who had localized disease in the extremities and were under age 30 had a favorable prognosis. Conclusions: Although Ewing sarcoma is a tumor affecting children and adolescents, it may be seen in adults, where the prognosis is generally worse. Although it is a highly malignant tumor, it is possible to achieve improved survival with combined modality treatments.

• Journal of Chest Surgery
• /
• 제26권1호
• /
• pp.47-53
• /
• 1993

The high relapse rate after curative surgery of lung cancer suggests that tumor cells are remained at the site of resection and in the distant organs. Postoperative radiochemoimmunotherapy including protein-bound polysaccharide PS-K[Copolang] and/or chemotherapy to improve the prognosis in lung cancer has been adopted. The patients with lung cancer who were treated with a combined modality therapy after surgery were reviewed to determine the effects of adjuvant immunotherapy[PS-K] and the relationship between midterm survival and clinicopathologic variables. During the past 5 years, 95 patients with lung cancer underwent resective operation. Of them, 30 cases were curative surgery, 29 were relative curative surgery, and the remainders were non-curative surgery. Postoperative combination therapies consisted of three types of therapies: postoperative BRM[biological response modifiers] with PS-K [Copolang] 50 mg/kg for 24 weeks[Group 1], chemoimmunotherapy with chemotherapy[a combination of cisplatin, etoposide, vindesine] and PS-K [Group 2], radioimmunotherapy with postoperative prophylactic irradiation to the mediastinum at total dose of 54 Gy-60 Gy and PS-K [Group 3] and surgery without adjuvant therapy[Group 4]. Twenty months survival rates of localized disease [Stages I and II] treated with PS-K, with radioimmunotherapy and no therapy were 73 %, 60 %, and 50 %, respectively [p [0.05]. Three-year survival rates of regionally advanced cases [stage Ilia and IIIb] were 23 % in Group 1.57 % in Group 2.20 % in Group 3, and 0 % in Group 4, respectively.According to above results, we suggest that postoperative combination therapy including PS-K might improve the prognosis of lung cancer. The similar survival pattern of patients with squamous cell carcinoma and adenocarcinoma treated with BRM, chemoimmunotherapy or radioimmunotherapy need to evaluate the role of postoperative immunotherapy[PS-K] in randomized studies.